Department of Pharmacy Services, St Joseph Mercy Health System, Ann Arbor, Michigan, USA.
Methods Consultants of Ann Arbor, Ypsilanti, Michigan, USA.
Clin Infect Dis. 2021 Apr 26;72(8):1404-1412. doi: 10.1093/cid/ciaa232.
β-Lactam antibiotics are first-line therapy for perioperative prophylaxis; however, patient-reported allergies often lead to increased prescribing of alternative antibiotics that may increase the incidence of surgical site infections. The R-group side chain of the β-lactam ring is responsible for allergic cross-reactivity and experts recommend the use of β-lactams that are structurally dissimilar.
An internally developed, antibiotic side-chain-based cross-reactivity chart was developed and implemented alongside enhanced allergy assessment processes. This single-center, quasi-experimental study analyzed antibiotic prescribing in all adult patients with a documented β-lactam allergy undergoing an inpatient surgical procedure between quartile (Q) 1 (2012)-Q3 (2014) (historical group) and Q3 (2016)-Q3 (2018) (intervention group). Propensity-weighted scoring analyses compared categorical and continuous outcomes. Interrupted time-series analysis further analyzed key outcomes.
A total of 1119 and 1089 patients were included in the historical and intervention cohorts, respectively. There was a significant difference in patients receiving a β-lactam alternative antibiotic between cohorts (84.9% vs 15.1%; P < .001). There was a decrease in 30-day readmissions in the intervention cohort (7.9% vs 6.3%; P = .035); however, there was no difference in the incidence of SSIs in patients readmitted (14.8% vs 13%; P = .765). No significant differences were observed in allergic reactions (0.5% vs 0.3%; P = .323), surgical site infections, in-hospital and 30-day mortality, healthcare facility-onset Clostridiodes difficile infection, acute kidney injury, or hospital costs.
Implementation of an antibiotic cross-reactivity chart combined with enhanced allergy assessment processes significantly improved the prescribing of β-lactam antibiotics for surgical prophylaxis.
β-内酰胺类抗生素是围手术期预防的一线治疗药物;然而,患者报告的过敏反应常常导致替代抗生素的开具增加,这可能会增加手术部位感染的发生率。β-内酰胺环的 R 基团侧链负责过敏交叉反应,专家建议使用结构上不同的β-内酰胺类药物。
开发了一种内部开发的、基于抗生素侧链的交叉反应图表,并与增强的过敏评估流程一起实施。这项单中心、准实验研究分析了在 2012 年第 1 季度至 2014 年第 3 季度(历史组)和 2016 年第 3 季度至 2018 年第 3 季度(干预组)期间,所有记录有β-内酰胺类药物过敏史并接受住院手术的成年患者的抗生素处方情况。基于倾向评分的评分分析比较了分类和连续结果。中断时间序列分析进一步分析了关键结果。
历史组和干预组分别纳入了 1119 名和 1089 名患者。两组患者接受β-内酰胺类替代抗生素的情况存在显著差异(84.9%比 15.1%;P<0.001)。干预组的 30 天再入院率下降(7.9%比 6.3%;P=0.035);然而,再入院患者的手术部位感染发生率没有差异(14.8%比 13%;P=0.765)。过敏反应(0.5%比 0.3%;P=0.323)、手术部位感染、住院和 30 天死亡率、医疗机构获得性艰难梭菌感染、急性肾损伤或医院费用均无显著差异。
实施抗生素交叉反应图表结合增强的过敏评估流程显著改善了手术预防用β-内酰胺类抗生素的处方。